The U.S. Food and Drug Administration (FDA) approved Risperdal Consta (risperidone) long-acting injection for the treatment of schizophrenia. It is the first long-acting, newer-generation (atypical) antipsychotic to be approved by the FDA. The treatment uses advanced technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks.

This addresses a major challenge in the treatment of schizophrenia and helps patients, clinicians and families/caregivers know with certainty that patients receive needed medication for this serious brain disorder. As many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis. This may lead to worsening of symptoms.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Alkermes Inc, developed Risperdal Consta. The product will be marketed by Janssen Pharmaceutica Products L.P.

Schizophrenia is a brain disorder that impairs a person's ability to think clearly, relate to others and distinguish between reality and imagination. It is estimated that more than 2 million Americans suffer from the condition. Atypical antipsychotic medications have become the most commonly prescribed treatments for schizophrenia, and many experts believe these medications have advantages over older medications. However, until now, these treatments have been available only in short-acting formulations.